Depiction of the elements of decision making used to determine appropriate efforts to achieve glycemic targets. Depiction of the elements of decision making.

Slides:



Advertisements
Similar presentations
Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections from a Diabetes Care Editors’ Expert Forum. Featured Article: Itamar Raz, M.D.,
Advertisements

3.4.1 Justify Marketing Strategies Appropriate to a Given Situation.
Admission Glucose and Mortality in Elderly Patients Hospitalized With Acute Myocardial Infarction by Mikhail Kosiborod, Saif S. Rathore, Silvio E. Inzucchi,
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Adapted from Montori et al,1 by permission of the publisher
Copyright © 2015 by the American Osteopathic Association.
Adapted from Montori et al,1 by permission of the publisher
Placebo Metformin ***p < vs placebo
Copyright © 2015 by the American Osteopathic Association.
Components of a CGM record over a 3
WHO KNOWS – HOW DO WE KNOW
Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.
Modulation of the intensiveness of glucose lowering in type 2 diabetes
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Volume 70, Issue 8, Pages (October 2006)
Goals. Achieving HbA1c Goals: Applying Guidelines to Intensify Therapy in Patients With Diabetes.
Sequential insulin strategies in type 2 diabetes.
Framework for understanding obesity in children and youth.
Rank-order bar chart of percentage of patient-days with blood glucose results > 299 mg/dl for non-ICU units. Rank-order bar chart of percentage of patient-days.
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
George Dailey, MD  Mayo Clinic Proceedings 
Summary of DURATION development program select efficacy results: absolute difference in change in A1C, body weight, systolic blood pressure, and LDL cholesterol.
Insulin and glucagon secretion: nondiabetic and diabetic subjects.
A: Kaplan-Meier estimate of time to first LLA
A summary of Lisa and Gerard, the two personas created during this study, including quotes that describe their attitude toward diabetes. A summary of Lisa.
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Depicted are patient and disease factors used to determine optimal A1C targets. Depicted are patient and disease factors used to determine optimal A1C.
PWD confidence with key diabetes management activities.
Flowchart of literature search for the effect of fructose on glycemic end points (fasting glucose, fasting insulin, and glycated blood proteins [HbA1c.
The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.
Modern Advances in Glucose Monitoring
Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.
Model of deterioration over time and potential interventions to identify and mitigate. Model of deterioration over time and potential interventions to.
Change in HbA1c and weight compared with baseline variables for the liraglutide group and the placebo group. Change in HbA1c and weight compared with baseline.
(A) Correlation between change in HbA1c and change in weight from baseline to week 24 in the liraglutide group. (A) Correlation between change in HbA1c.
Adjusted annual percentage of quality indicators by prescription
(A) Rate of achieving targets for glycated hemoglobin (HbA1c), blood pressure (BP), and lipids in all subjects and (B) prevalence of nephropathy, retinopathy,
Inclusion process. Inclusion process. Of 5200 eligible patients, 204 declined participation, 111 had diabetes >400 days before All New Diabetics in Scania.
Association between antibiotic purchases and glycated hemoglobin (HbA1c) values in patients with and without diabetic nephropathy. Association between.
Left: Baseline brain white and gray matter uptake rates of [18F]-FTHA (A) and [11C]-palmitate (B). Left: Baseline brain white and gray matter uptake rates.
Glucose-lowering medication in type 2 diabetes: overall approach.
What’s your nationality? Where are you from?
Percentage of Florida adults with diagnosed diabetes who received services or engaged in self-management practices by DSME duration category, Florida BRFSS.
Mean LOS and 30-day all-cause readmission rates before and after conversion to the Interdisciplinary Diabetes Care model. Mean LOS and 30-day all-cause.
Saxagliptin improves glycemic control in younger and older individuals with type 2 diabetes. Saxagliptin improves glycemic control in younger and older.
Associations of body mass index (BMI) levels with achieving targets for glycated hemoglobin (HbA1c), blood pressure (BP), and lipids in the upper panels.
Figure 6 Multiple target epitopes exist in the N-terminal domains of Caspr2 (A) Multidomain deletion constructs of Caspr2 were generated to determine which.
Health profile used in workshops to help people make diabetes management decisions. Health profile used in workshops to help people make diabetes management.
The possible off-target effect of increased heart failure hospitalizations from saxagliptin in the SAVOR trial. The possible off-target effect of increased.
Patient flowchart of recruitment and treatment failure and success with glyburide vs. metformin. Patient flowchart of recruitment and treatment failure.
Changes in glycated hemoglobin (HbA1c) levels after 12 weeks’ treatment with lixisenatide (according to dose increase regimen) or placebo. Changes in glycated.
Glycemic control and body weight over 52 weeks.
Protocol for Management of Adult Patients with Diabetic Ketoacidosis
A: Forest plot of Peto odds ratios (ORs) of main glycemic end points, as defined in each trial, from published RCTs of bariatric/metabolic surgery compared.
Correlation between serum visfatin concentrations and the clinical stage (A) and tumor size (B, C) of HCCs. A and B, the correlations were determined by.
A: Probability of retinopathy-free survival.
Algorithm for management of patients with pain due to DSPN
Mean HbA1c (%) and estimated marginal mean SH rate (per 100 patient-years) adjusted for sex, age-group at diagnosis, and diabetes duration, by time period,
Postoperative blood glucose levels and total insulin requirement.
Pathway to initial antihypertensive therapy in patients with diabetes
Prevalence of nephropathy, retinopathy, and neuropathy in subjects achieving all (A) three targets, (B) two targets, (C) one target, and (D) none, and.
Upper panel: For performance of the 10-g monofilament test, the device is placed perpendicular to the skin, with pressure applied until the monofilament.
Section 6: Update on lipid treatment guidelines
Fig. 1. Antihyperglycemic therapy algorithm for adult patients with type 2 diabetes mellitus (T2DM). The algorithm stratifies the choice of medications.
Novel presentation of glucose data from a patient with type 1 diabetes
© The Author(s) Published by Science and Education Publishing.
A, Setting code for the Sophysa Sophy SM8 valve.
Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.
Benchmarking scatterplot for non-ICU units.
Presentation transcript:

Depiction of the elements of decision making used to determine appropriate efforts to achieve glycemic targets. Depiction of the elements of decision making used to determine appropriate efforts to achieve glycemic targets. Greater concerns about a particular domain are represented by increasing height of the ramp. Thus, characteristics/predicaments toward the left justify more stringent efforts to lower HbA1c, whereas those toward the right are compatible with less stringent efforts. Where possible, such decisions should be made in conjunction with the patient, reflecting his or her preferences, needs, and values. This “scale” is not designed to be applied rigidly but to be used as a broad construct to help guide clinical decisions. Adapted with permission from Ismail-Beigi et al.20 Silvio E. Inzucchi et al. Diabetes Spectr 2012;25:154-171 ©2012 by American Diabetes Association